The effect of thiazolidinediones on bone mineral density in Chinese older patients with type 2 diabetes

Journal of Bone and Mineral Metabolism

Volumn 28, Issue 1, 2010, Pages 77-81

  Li, Hong ^a   Cui, Ran ^a   Cai, Haidong ^a   Wu, Guoting ^a   Lv, Zhongwei ^a   Sheng, Chunjun ^a   Cheng, Xiaoyun ^a   Li, Fang ^a   Yu, Yongchun ^a  

^a TONGJI UNIVERSITY   (China)

Author keywords

Bone mineral density; Diabetes mellitus type 2; Osteoporosis; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; CARBOXY TERMINAL TELOPEPTIDE; GLICLAZIDE; GLIPIZIDE; GLIQUIDONE; HEMOGLOBIN A1C; INSULIN; METFORMIN; NATEGLINIDE; OSTEOCALCIN; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BONE DENSITY; BONE METABOLISM; CHINESE; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG EFFECT; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; GLYCEMIC CONTROL; HUMAN; LONG TERM CARE; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL EXAMINATION; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; URINALYSIS;

AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; BODY MASS INDEX; BONE AND BONES; BONE DENSITY; BONE REMODELING; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEX CHARACTERISTICS; THIAZOLIDINEDIONES;

EID: 76949093228     PISSN: 09148779     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00774-009-0104-4     Document Type: Article

References (31)

1. K Oshima A Nampei M Matsuda M Iwaki A Fukuhara J Hashimoto H Yoshikawa I Shimomura 2005 Adiponectin increases bone mass by suppressing osteoclast and activating osteoblast Biochem Biophys Res Commun 331 520 526 10.1016/j.bbrc.2005.03.210 1:CAS:528:DC%2BD2MXjsFGrtbw%3D 15850790 (Pubitemid 40602668)
2. S Watanabe Y Takeuchi S Fukumoto H Fujita T Nakano T Fujita 2003 Decrease in serum leptin by troglitazone is associated with preventing bone loss in type 2 diabetic patients J Bone Miner Metab 21 166 171 10.1007/s007740300026 1:CAS:528:DC%2BD3sXjt1Gju70%3D 12720051 (Pubitemid 41184298)
3. R Okazaki M Toriumi S Fukumoto M Miyamoto T Fujita K Tanaka Y Takeuchi 1999 Thiazolidinediones inhibit osteoclast-like cell formation and bone resorption in vitro Endocrinology 140 5060 5065 10.1210/en.140.11.5060 1:CAS:528:DyaK1MXmvFemsbc%3D 10537132 (Pubitemid 30687113)
4. AV Schwartz DE Sellmeyer E Vittinghoff L Palermo B Lecka-Czernik KR Feingold ES Strotmeyer HE Resnick L Carbone BA Beamer SW Park NE Lane TB Harris SR Cummings 2006 Thiazolidinedione use and bone loss in older diabetic adults J Clin Endocrinol Metab 91 3349 3354 10.1210/jc.2005-2226 1:CAS:528: DC%2BD28Xpslajt74%3D 16608888 (Pubitemid 44402103)
5. SE Kahn B Zinman JM Lachin SM Haffner WH Herman RR Holman BG Kravitz D Yu MA Heise RP Aftring G Viberti 2008 Rosiglitazone-associated fractures in type 2 diabetes: an analysis from ADOPT Diabetes Care 31 845 851 10.2337/dc07-2270 1:CAS:528:DC%2BD1cXmsFGrt7o%3D 18223031
6. N Maeda M Takahashi T Funahashi S Kihara H Nishizawa K Kishida H Nagaretani M Matsuda R Komuro N Ouchi H Kuriyama K Hotta T Nakamura I Shimomura Y Matsuzawa 2001 PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein Diabetes 50 2094 2099 10.2337/diabetes.50.9.2094 1:CAS:528:DC%2BD3MXmsFKns7k%3D 11522676
7. TP Combs JA Wagner J Berger T Doebber WJ Wang BB Zhang M Tanen AH Berg S O'Rahilly DB Savage K Chatterjee S Weiss PJ Larson KM Gottesdiener BJ Gertz MJ Charron PE Scherer DE Moller 2002 Induction of adipocyte complement-related protein of 30 kDa by PPAR gamma agonists: a potential mechanism of insulin sensitization Endocrinology 143 998 1007 10.1210/en.143.3.998 1:CAS:528:DC%2BD38XhvVeis7o%3D 11861525 (Pubitemid 34164048)
8. CV Rizos MS Elisaf DP Mikhailidis EN Liberopoulos 2009 How safe is the use of thiazolidinediones in clinical practice? Expert Opin Drug Saf 8 15 32 10.1517/14740330802597821 1:CAS:528:DC%2BD1MXnsVWitA%3D%3D 19236215
9. Schwartz AV (2008) TZDs and Bone: a review of the recent clinical evidence. PPAR Res 2008:297893
10. A Grey 2008 Thiazolidinedione-induced skeletal fragility-mechanisms and implications Diabetes Obes Metab 11 275 284 10.1111/j.1463-1326.2008.00931.x 18671797
11. YK Loke S Singh CD Furberg 2009 Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis CMAJ 6 32 39
12. S Singh YK Loke 2008 The safety of rosiglitazone in the treatment of type 2 diabetes Expert Opin Drug Saf 7 579 585 10.1517/14740338.7.5.579 1:CAS:528:DC%2BD1cXhtVGktrbO 18759710
13. AK McDonough RS Rosenthal X Cao KG Saag 2008 The effect of thiazolidinediones on BMD and osteoporosis Nat Clin Pract Endocrinol Metab 4 507 513 10.1038/ncpendmet0920 1:CAS:528:DC%2BD1cXhtVSitrrM 18695700
14. C Meier ME Kraenzlin M Bodmer SS Jick H Jick CR Meier 2008 Use of thiazolidinediones and fracture risk Arch Intern Med 28 820 825 10.1001/archinte.168.8.820 (Pubitemid 351620084)
15. CE Murphy PT Rodgers 2007 Effects of thiazolidinediones on bone loss and fracture Ann Pharmacother 41 2014 2018 10.1345/aph.1K286 1:CAS:528: DC%2BD2sXhsVGltrfF 17940125 (Pubitemid 350230570)
16. P Vestergaard 2009 Bone metabolism in type 2 diabetes and role of thiazolidinediones Curr Opin Endocrinol Diabetes Obes 16 125 131 1:CAS:528:DC%2BD1MXjtlOqtL0%3D 19300092
17. S Benvenuti I Cellai P Luciani C Deledda S Baglioni C Giuliani R Saccardi B Mazzanti S Dal Pozzo E Mannucci A Peri M Serio 2007 Rosiglitazone stimulates adipogenesis and decreases osteoblastogenesis in human mesenchymal stem cells J Endocrinol Invest 30 RC26 30 1:CAS:528:DC%2BD1cXitFyksg%3D%3D 17993761
18. AA Ali RS Weinstein SA Stewart AM Parfitt SC Manolagas RL Jilka 2005 Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation Endocrinology 146 1226 1235 10.1210/en.2004-0735 1:CAS:528:DC%2BD2MXitlehtro%3D 15591153 (Pubitemid 40289310)
19. JT Crossno Jr SM Majka T Grazia RG Gill DJ Klemm 2006 Rosiglitazone promotes development of a novel adipocyte population from bone marrow-derived circulating progenitor cells J Clin Invest 116 3220 3228 10.1172/JCI28510 1:CAS:528:DC%2BD28XhtlWgsbnN 17143331 (Pubitemid 44878636)
20. K Takagi A Kudo 2008 Bone marrow stromal cell lines having high potential for osteoclast-supporting activity express PPARgamma1 and show high potential for differentiation into adipocytes J Bone Miner Metab 26 13 23 10.1007/s00774-007-0787-3 18095059 (Pubitemid 350308000)
21. SH Hung CH Yeh HT Huang P Wu ML Ho CH Chen C Wang D Chao GJ Wang 2008 Pioglitazone and dexamethasone induce adipogenesis in D1 bone marrow stromal cell line, but not through the peroxisome proliferator-activated receptor-gamma pathway Life Sci 12 561 569 10.1016/j.lfs.2007.11.033
22. MA Sorocéanu D Miao XY Bai H Su D Goltzman AC Karaplis 2004 Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis J Endocrinol 183 203 216 10.1677/joe.1.05723 15525588 (Pubitemid 40124657)
23. B Lecka-Czernik C Ackert-Bicknell ML Adamo V Marmolejos GA Churchill KR Shockley IR Reid A Grey CJ Rosen 2007 Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo Endocrinology 148 903 911 10.1210/en.2006-1121 1:CAS:528: DC%2BD2sXhtlOjurw%3D 17122083 (Pubitemid 46143190)
24. Y Wan LW Chong RM Evans 2007 PPAR-gamma regulates osteoclastogenesis in mice Nat Med 13 1496 1503 10.1038/nm1672 1:CAS:528:DC%2BD2sXhtl2gs7bM 18059282 (Pubitemid 350224244)
25. A Grey 2008 Skeletal consequences of thiazolidinedione therapy Osteoporos Int 19 129 137 10.1007/s00198-007-0477-y 1:CAS:528:DC%2BD1cXitVSquw%3D%3D 17901911
26. AV Schwartz DE Sellmeyer 2008 Effect of thiazolidinediones on skeletal health in women with type 2 diabetes Expert Opin Drug Saf 7 69 78 10.1517/14740338.7.1.69 1:CAS:528:DC%2BD1cXoslek 18171315 (Pubitemid 351222964)
27. SE Kahn SM Haffner MA Heise WH Herman RR Holman NP Jones 2006 Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy N Engl J Med 355 2427 2443 10.1056/NEJMoa066224 1:CAS:528:DC%2BD28Xht12ntrzF 17145742 (Pubitemid 44903747)
28. GL Rubin Y Zhao AM Kalus ER Simpson 2000 Peroxisome proliferator- activated receptor γ ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implications for breast cancer therapy Cancer Res 60 1604 1608 1:CAS:528:DC%2BD3cXit1aqt7c%3D 10749129
29. C Fürnsinn P Nowotny B Brunmair F Gras M Roden W Waldhäusl H Vierhapper 2002 Thiazolidinediones influence plasma steroids of male obese Zucker rats Endocrinology 143 327 10.1210/en.143.1.327 11751625 (Pubitemid 34056435)
30. D Seto-Young M Paliou J Schlosser D Avtanski A Park P Patel K Holcomb P Chang L Poretsky 2005 Direct thiazolidinedione action in the human ovary: insulin-independent and insulin-sensitizing effects on steroidogenesis and insulin-like growth factor binding protein-1 production J Clin Endocrinol Metab 90 6099 6105 10.1210/jc.2005-0469 1:CAS:528:DC%2BD2MXht1alt7bE 16131582 (Pubitemid 41606531)
31. H Vierhapper P Nowotny W Waldhausl 2003 Reduced production rates of testosterone and dihydrotestosterone in healthy men treated with rosiglitazone Metabolism 52 230 232 10.1053/meta.2003.50028 1:CAS:528:DC%2BD3sXhtlClt7g%3D 12601638 (Pubitemid 36388849)